Cover image of HUMAN PROOF OF CONCEPT
(12)
Health & Fitness
Medicine
Science

HUMAN PROOF OF CONCEPT

Updated 1 day ago

Health & Fitness
Medicine
Science
Read more

The Biotech Venture Capital Podcast

Read more

The Biotech Venture Capital Podcast

iTunes Ratings

12 Ratings
Average Ratings
10
1
1
0
0

Deconstructing biotech

By this custard - Jan 12 2016
Read more
Enjoyed the first few podcasts. Janelle has a defusing style that makes her guests relatable, and offers valuable insight into a complex field.

iTunes Ratings

12 Ratings
Average Ratings
10
1
1
0
0

Deconstructing biotech

By this custard - Jan 12 2016
Read more
Enjoyed the first few podcasts. Janelle has a defusing style that makes her guests relatable, and offers valuable insight into a complex field.
Cover image of HUMAN PROOF OF CONCEPT

HUMAN PROOF OF CONCEPT

Updated 1 day ago

Read more

The Biotech Venture Capital Podcast

Rank #1: Stacey Seltzer on VC: Timing Timing Timing

Podcast cover
Read more

If the mantra in real estate is location location location, for venture capital it might just be timing timing timing. Stacey Seltzer made the move from big pharma into venture capital during a financial crisis and has gone on to build a wildly diverse portfolio of healthcare companies at Aisling Capital. She takes us on a tour of some of the highlights, and reveals what venture capitalists do for fun.

Feb 28 2017
31 mins
Play

Rank #2: Deborah Dunsire: Business XTuition

Podcast cover
Read more

Deborah Dunsire was a general practitioner in South Africa when a motorcycle drove her into industry. And that side trip, ultimately routing her to Boston, is still going on. She built the North American Oncology unit at Novartis, launched Gleevec, ran Millennium after the millennium, realized the value in Velcade, took a foray into Forum, and recently announced her latest role, President and CEO of XTuit Pharmaceuticals

Apr 30 2017
35 mins
Play

Rank #3: The Multivalent Mathai Mammen

Podcast cover
Read more
In the late nineties, a company named "Advanced Medicine" came together with the 4Cs of entrepreneurship in place: a concept, co-founders, capital, and some well-placed cold-calls. Mathai Mammen was one of those co-founders, still living in a dorm at the time. The company's investors evolved, it renamed itself, went public, and ultimately split into two independent companies: Innoviva (INVA) and Theravance Biopharma (TBPH).

Today, Mathai is the SVP of R&D at Theravance Biopharma. Under his leadership, they have always done things a little differently. In the beginning they used their seed capital to build an in-house vivarium. They have discovered all of their development candidates - 31 and counting - internally or collaboratively. And after 3 approvals, they left their royalty stream to Innoviva and struck out on their own to focus on R&D - because "it's difficult to be innovative when you're in the shadows."

Mathai has had a longstanding reputation as one of the good guys in the industry, but in recent years he has doubled down. After two extraordinary family tragedies, he calls out the importance of persistence, humility, and empathy above all - both in and outside of business.
Feb 02 2016
42 mins
Play

Rank #4: Ron Cohen: Founder & Confounder (Part 1)

Podcast cover
Read more
Ron Cohen has defied Venture Capital wisdom by founding Acorda Therapeutics over 20 years ago and remaining the CEO to this day.  Originally hearing "no" from 70 VCs, he nevertheless grew the company into a public biotech worth nearly $2B today.  As unlikely as that has been, there would've been no Acorda had he found more success on Broadway.
Ron discusses his road from Jeopardy! champion to entrepreneur, the role played by his flat head and great hair, and what on earth could motivate someone to invest in drug development. He also explains how upstate NY does not start at 96th St.
The two-part interview continues in the following episode, Part 2.
Jan 06 2016
30 mins
Play

Rank #5: Glen de Vries has his Head in the Cloud

Podcast cover
Read more
In 1999 Glen de Vries started a tech company in his 5th floor walkup - very much the NYC equivalent of a garage in Silicon Valley. Today Medidata Solutions continues to transform human drug studies with their clinical cloud platform. They are approaching 3M patients and a $3B market cap.
Glen explains how he plans to reach escape velocity with no exit strategy.  
And how he keeps his feet on the dance floor and head in the cloud.
Dec 08 2016
32 mins
Play

Rank #6: Greg Verdine will not take “undruggable” for an answer

Podcast cover
Read more
Greg Verdine has evolved from merely being a Harvard prof, to consulting for big pharma, to starting biotech companies, to being a Venture Partner, and even to co-founding a non-profit institute – not just sequentially, but largely in parallel.

He has teamed up with Third Rock Ventures, TPG Biotech, AppleTree Partners, and he unveils his brand new gig with WuXi Ventures.

Greg co-founded the biotechs Enanta (ENTA), Tokai (TKAI), Gloucester (now Celgene), Aileron, Warp Drive, WaVe (WVE), and Fog. His day job today, if forced to list just one, is CSO of Warp Drive Bio. He reveals a couple of secrets about Warp Drive strategy and lifts the fog off of Fog Pharma, his latest – and still stealth – newco.

As different as these companies are, a common theme runs through them: to cure the incurable by drugging the undruggable.  With apologies to Star Trek, that is Greg’s personal mission: to boldly go where no drug has gone before.

In fact Greg wants to blow up the conventional meaning for the word "drug". He sees beyond the pharma industry’s small molecules plus the biotech industry’s biologics, because they seem positively “puny” in the context of human biology. And he has clever tricks and other modalities at his disposal – not to mention the blueprints: 135,000 bacterial genomes, where the answers cannot hide.
Mar 16 2016
30 mins
Play

Rank #7: Francois Nader: Be Small But Think Big

Podcast cover
Read more
Today, Francois Nader is merely President of the Jesra Foundation, trustee of the New Jersey Chamber of Commerce, Chairman of Acceleron Pharma (XLRN), Director of ArRETT Neuroscience, Clementia Pharma, and Advanced Accelerator Applications (AAAP), and Advisory Board member of the Open Future Institute.

But you might remember him from such former roles as President, CEO and Executive Director of NPS Pharma (NPSP now Shire) prior to its $5.2B acquisition, Venture Partner at Care Capital, 2013 Ernst and Young National Life Science Entrepreneur of the Year, Chairman of BioNJ, and Board member of BIO, Noven (NOVN), Trevena (TRVN), and Baxalta (BXLT now also Shire).

He joins me to describe the art of being small while thinking big, and to share some decidedly unconventional wisdom.
Sep 30 2016
33 mins
Play

Rank #8: Bill Newell: Sutro has an Unfair Advantage

Podcast cover
Read more
Bill Newell is a lawyer turned large molecule wrangler. He’s CEO of Sutro Biopharma, and their special sauce - literally - lets them manipulate and manufacture antibodies with the kind of control scientists have had over small molecules for decades.

Where other biotechs find scientific challenges can threaten their survival, with Sutro it comes down to strategic challenges. And Bill has led them to enviable partnerships, capital, and optionality.

Sutro has an unfair advantage: Bill Newell.
Aug 31 2016
34 mins
Play

Rank #9: Brian Bloom: Hockey Sticks and Cheerleaders Do Not Go Together

Podcast cover
Read more
Home or away, Brian Bloom is recognized for his wildly successful conference and boutique investment bank.

With a mission to uncover and cultivate Canadian life sciences companies through scientific focus and range of services, Bloom Burton & Co., which he co-founded in 2008, has risen swiftly to be profitable and globally unique.

And its Bloom Burton Healthcare Investor Conference achieved actual hockey stick growth since it broke onto the Canadian biotech scene 5 years ago.

But hockey and cheerleaders do not go together. Brian’s knowledge of the Canadian biotech scene, and his seat on umpteen boards, leads him to a frank, no-apologies stance on the industry.
Jul 31 2016
33 mins
Play

Rank #10: Sven Jacobson Doesn’t Have a Swelled Head

Podcast cover
Read more
Have you heard the one about the guy who founded a biotech startup in the middle of Manhattan? Around a repurposed, hydrolysable, insoluble small molecule? To treat massive strokes, traumatic brain injury, and other neuro indications? Using a highly translatable rodent model? During the financial crisis? Unpartnered? And who spent $1M per year to generate randomized, placebo-controlled, double-blind PhII results that show a 50% reduction in mortality from strokes that were too big for other trials and too late for other treatments?

That’s Sven Jacobson. He is CEO of Remedy Pharmaceuticals, and was Partner at Carrot Capital Healthcare Ventures, the nontraditional VC that founded and funded Remedy.

For a long time, Remedy was one guy and one drug. But that drug, Cirara™, combats swelling in the central nervous system - a root cause of morbidity and mortality in multiple diseases. Today Cirara™ is still investigational, but in line to be the first therapeutic advance in the stroke field in over 20 years. And an in-progress Ph II trial in TBI has it poised to tackle football as well.

Sven doesn't have a swelled head - and he doesn't want anyone else to have one either.
May 23 2016
33 mins
Play

Similar Podcasts